-+ 0.00%
-+ 0.00%
-+ 0.00%

Truist Securities Maintains Buy on Agios Pharmaceuticals, Lowers Price Target to $36

Benzinga·04/30/2026 12:37:00
Listen to the news
Truist Securities analyst Gregory Renza maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Buy and lowers the price target from $39 to $36.